Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R/R)Befloxatone SCHEMBL9482918 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| Befloxatone SCHEMBL464941 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| (R/R)Befloxatone SCHEMBL9463277 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| (R/R)Befloxatone SCHEMBL9463614 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| (R/R)Befloxatone SCHEMBL6455164 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| (R/R)Befloxatone SCHEMBL9462907 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| (R/R)Befloxatone SCHEMBL9463708 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| SCHEMBL9484172 | 0.93 | GRM2 (0.52) | GRM2MAOB | |
| SCHEMBL9484176 | 0.93 | GRM2 (0.52) | GRM2MAOB | |
| SCHEMBL9465260 | 0.90 | GRM2 (0.51) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694014-B2 | Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors | UNIVERSITA DEGLI STUDI DI PADOVA (IT) | 2017-07-04 | — | — | US | disclosed |
| US-20150290201-A1 | TREATMENT OF MUSCULAR DYSTROPHIES AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS | UNIV PADOVA (IT) | 2015-10-15 | — | — | US | disclosed |
| US-8487008-B2 | Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors | UNIVERSITA DEGLI STUDI DI PADOVA (IT) | 2013-07-16 | — | — | US | disclosed |
| US-20130142821-A1 | Hapten-Carrier Conjugates and Uses Thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2013-06-06 | — | — | US | disclosed |
| US-20120329800-A1 | TREATMENT OF MUSCULAR DYSTROPHIES AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS | UNIVERSITA' DEGLI STUDI DI PADOVA, (UNIVERSITY OF PADUA) | 2012-12-27 | — | — | US | disclosed |
| US-8187607-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2012-05-29 | — | — | US | disclosed |
| EP-2392345-A2 | Hapten-carrier conjugates comprising virus like particles and uses thereof | Cytos Biotechnology AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100129395-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-7452541-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20050281845-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-12-22 | — | — | US | disclosed |
| US-6932971-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-08-23 | — | — | US | disclosed |
| EP-1523334-A2 | HAPTEN-CARRIER CONJUGATES AND USES THEREOF | Cytos Biotechnology AG (CH) | 2005-04-20 | — | — | EP | disclosed |
| EP-1307182-B1 | PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL DELIVERY OF BEFLOXATONE | SANOFI AVENTIS (FR) | 2005-03-30 | — | — | EP | disclosed |
| US-20040059094-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2004-03-25 | — | — | US | disclosed |
| WO-2004009116-A2 | HAPTEN-CARRIER CONJUGATES COMPRISING VIRUS LIKE PARTICLES AND USES THEREOF | CYTOS BIOTECHNOLOGY AG (CH) | 2004-01-29 | — | — | WO | disclosed |
| EP-0736606-B1 | Process for the enzymatic preparation of intermediates for the synthesis of befloxatone | SANOFI SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| EP-0736606-A1 | Process for the enzymatic preparation of intermediates for the synthesis of befloxatone | SYNTHELABO (FR) | 1996-10-09 | — | — | EP | disclosed |
| US-5264443-A | Psychotropic drugs, antidepressants and anxiolytic agents | DELALANDE S.A. (FR) | 1993-11-23 | — | — | US | disclosed |
| US-5196543-A | Antidepressants, tranquilizers | DELALANDE S.A. (FR) | 1993-03-23 | — | — | US | disclosed |
| US-5036091-A | Psychotropic drugs | DELALANDE S.A. (FR) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290201-A1 | TREATMENT OF MUSCULAR DYSTROPHIES AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS | MAOA, MAOB, MUSK | GRM2 1157/4885MAOB 2/4885 |
| US-20120329800-A1 | TREATMENT OF MUSCULAR DYSTROPHIES AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS | MAOA, MAOB, MUSK | GRM2 1157/4885MAOB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.